AbbVie Revenue 2010-2023 | ABBV
AbbVie annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- AbbVie revenue for the quarter ending December 31, 2023 was $14.301B, a 5.42% decline year-over-year.
- AbbVie revenue for the twelve months ending December 31, 2023 was $54.318B, a 6.44% decline year-over-year.
- AbbVie annual revenue for 2023 was $54.318B, a 6.44% decline from 2022.
- AbbVie annual revenue for 2022 was $58.054B, a 3.3% increase from 2021.
- AbbVie annual revenue for 2021 was $56.197B, a 22.69% increase from 2020.
AbbVie Annual Revenue
(Millions of US $) |
| 2023 |
$54,318 |
| 2022 |
$58,054 |
| 2021 |
$56,197 |
| 2020 |
$45,804 |
| 2019 |
$33,266 |
| 2018 |
$32,753 |
| 2017 |
$28,216 |
| 2016 |
$25,638 |
| 2015 |
$22,859 |
| 2014 |
$19,960 |
| 2013 |
$18,790 |
| 2012 |
$18,380 |
| 2011 |
$17,444 |
| 2010 |
$15,638 |
| 2009 |
$14,214 |
AbbVie Quarterly Revenue
(Millions of US $) |
| 2023-12-31 |
$14,301 |
| 2023-09-30 |
$13,927 |
| 2023-06-30 |
$13,865 |
| 2023-03-31 |
$12,225 |
| 2022-12-31 |
$15,121 |
| 2022-09-30 |
$14,812 |
| 2022-06-30 |
$14,583 |
| 2022-03-31 |
$13,538 |
| 2021-12-31 |
$14,886 |
| 2021-09-30 |
$14,342 |
| 2021-06-30 |
$13,959 |
| 2021-03-31 |
$13,010 |
| 2020-12-31 |
$13,858 |
| 2020-09-30 |
$12,902 |
| 2020-06-30 |
$10,425 |
| 2020-03-31 |
$8,619 |
| 2019-12-31 |
$8,704 |
| 2019-09-30 |
$8,479 |
| 2019-06-30 |
$8,255 |
| 2019-03-31 |
$7,828 |
| 2018-12-31 |
$8,305 |
| 2018-09-30 |
$8,236 |
| 2018-06-30 |
$8,278 |
| 2018-03-31 |
$7,934 |
| 2017-12-31 |
$7,739 |
| 2017-09-30 |
$6,995 |
| 2017-06-30 |
$6,944 |
| 2017-03-31 |
$6,538 |
| 2016-12-31 |
$6,796 |
| 2016-09-30 |
$6,432 |
| 2016-06-30 |
$6,452 |
| 2016-03-31 |
$5,958 |
| 2015-12-31 |
$6,400 |
| 2015-09-30 |
$5,944 |
| 2015-06-30 |
$5,475 |
| 2015-03-31 |
$5,040 |
| 2014-12-31 |
$5,452 |
| 2014-09-30 |
$5,019 |
| 2014-06-30 |
$4,926 |
| 2014-03-31 |
$4,563 |
| 2013-12-31 |
$5,111 |
| 2013-09-30 |
$4,658 |
| 2013-06-30 |
$4,692 |
| 2013-03-31 |
$4,329 |
| 2012-12-31 |
$5,206 |
| 2012-09-30 |
$4,508 |
| 2012-06-30 |
$4,493 |
| 2012-03-31 |
$4,173 |
| 2011-12-31 |
$4,864 |
| 2011-09-30 |
$4,409 |
| 2011-06-30 |
$4,274 |
| 2011-03-31 |
$3,897 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$287.801B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
